Decision support for precision oncology: Evolving from monotherapy to genomically informed combinations
Decision support for precision oncology: Evolving from monotherapy to genomically informed combinations
CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Systems immunology in immuno-oncology
Highlights from WIN 2019
Innovation in clinical trials: WINTHER trial
A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations
Rapidly changing landscape of precision medicine in Japan
Integration of DNA and RNA investigations in clinical trials: A laboratory challenge
Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours
Implementing national cancer control plans
Comment: POLO III trial for metastatic pancreatic cancer
Tackling the increase in cancer cases worldwide